| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income - EUR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Expenses - EUR | 506 | 576 | 350 | 9 | 64 | 443 | 114 | 12 | 0 | 0 |
| Gross Profit/Loss - EUR | -506 | -576 | -350 | -9 | -64 | -443 | -114 | -12 | 0 | 0 |
| Net Profit/Loss - EUR | -506 | -576 | -350 | -9 | -64 | -443 | -114 | -12 | 0 | 0 |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Ilgriofarm S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 8.110 | 8.027 | 7.891 | 7.746 | 7.596 | 7.452 | 7.173 | 7.195 | 7.174 | 7.133 |
| Current Assets | 570 | 567 | 569 | 550 | 475 | 24 | 23 | 11 | 11 | 11 |
| Inventories | 482 | 486 | 478 | 460 | 451 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 68 | 67 | 66 | 65 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash | 20 | 14 | 25 | 24 | 24 | 24 | 23 | 11 | 11 | 11 |
| Shareholders Funds | -5.406 | -5.926 | -6.176 | -6.071 | -6.018 | -6.346 | -6.320 | -6.351 | -6.332 | -6.297 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 14.085 | 14.521 | 14.636 | 14.368 | 14.089 | 13.822 | 13.516 | 13.558 | 13.517 | 13.441 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Ilgriofarm S.r.l.